$1.39
13.01% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US7530181004
Symbol
RANI
Sector
Industry

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock price

$1.39
-0.08 5.44% 1M
-0.82 37.10% 6M
+0.02 1.46% YTD
-1.75 55.73% 1Y
-12.71 90.14% 3Y
-9.61 87.36% 5Y
-9.61 87.36% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.16 13.01%
ISIN
US7530181004
Symbol
RANI
Sector
Industry

Key metrics

Market capitalization $40.97m
Enterprise Value $44.04m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 42.76
P/S ratio (TTM) P/S ratio 39.78
P/B ratio (TTM) P/B ratio 20.64
Revenue (TTM) Revenue $1.03m
EBIT (operating result TTM) EBIT $-49.60m
Cash position $28.14m
EPS (TTM) EPS $-1.06
P/E forward negative
Short interest 11.62%
Show more

Is Rani Therapeutics Holdings Inc - Ordinary Shares Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:

Buy
100%

Financial data from Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1.03 1.03
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 27 27
33% 33%
2,590%
- -
-
-
- Depreciation and Amortization 1.03 1.03
36% 36%
100%
EBIT (Operating Income) EBIT -50 -50
25% 25%
-4,816%
Net Profit -30 -30
12% 12%
-2,915%

In millions USD.

Don't miss a Thing! We will send you all news about Rani Therapeutics Holdings Inc - Ordinary Shares Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock News

Neutral
Seeking Alpha
2 days ago
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Talat Imran - CEO Svai Sanford - CFO Conference Call Participants Annabel Samimy - Stifel Eka Gigauri - Oppenheimer Julian Harrison - BTIG Mitchell Kapoor - H.C. Wainwright Chad Yahn - Maxim Group Xinwei An - Canaccord Genuity John Vand...
Neutral
GlobeNewsWire
2 days ago
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 -
Neutral
GlobeNewsWire
7 days ago
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e –
More Rani Therapeutics Holdings Inc - Ordinary Shares Class A News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on April 6, 2021 and is headquartered in San Jose, CA.

Head office United States
CEO Talat Imran
Employees 105
Founded 2012
Website www.ranitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today